Tavira Therapeutics develops an advanced platform that enhances AAV (adeno-associated virus) gene delivery.
Tavira Therapeutics has raised $357K in total funding. The most recent round was Grant. The last funding was announced in February 2025.
Tavira Therapeutics's investors include Gemma Frisius Fund, General Inception, Flanders Innovation & Entrepreneurship (VLAIO).
Tavira Therapeutics is headquartered in Teuven, Belgium.
Tavira Therapeutics develops an advanced platform that enhances AAV (adeno-associated virus) gene delivery.
Tavira Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tavira Therapeutics — Funding & Investors." VCBacked, February 4, 2025, https://www.vcbacked.co/company/tavira-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Tavira Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tavira-therapeutics
{{cite web |title=Tavira Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tavira-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated